Xiaoyan Cathy Zou

Experienced in scientific review writing, project management and presentation. Multidisciplinary background in cell biology, immunology, and biomolecular engineering. Accomplished Staff Scientist demonstrating strong knowledge of various scientific methods and research skills. Highly organized, proactive and punctual with team-oriented mentality.

1. Schneider CG, Fey J, Zou X, et al. Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection. Vaccine. 2022;40(31):4270-4280. 2. Langowski MD, Khan FA, Savransky S, Brown DR, Balasubramaniyam A, Harrison WB, Zou X, et al. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum. NPJ Vaccines. 2022 Jan 27;7(1):13. 3. Mallory KL, Taylor JA, Zou X, et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines. 2021;6(1):84. 4. Livingstone, M. C., Bitzer, A. A., Giri, A., Luo, K., Sankhala, R. S., Choe, M., Zou, X.,et al. In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). Scientific Reports. 2021 Mar 5;11(1):5318. 5. Langowski MD, Khan FA, Bitzer AA, Genito CJ, Schrader AJ, Martin ML, Soto K, Zou X, et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. PNAS. 2020 Feb 11;117(6):3114-3122. 6. Winer B, Edgel KA, Zou X, et al. Identification of Plasmodium falciparum proteoforms from liver stage models. Malaria Journal. 2020 Jan 7;19(1):10. 7. Martin ML, Bitzer AA, Schrader A, Bergmann-Leitner ES, Soto K, Zou X, et al. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin. Malaria Journal. 2019 Nov 27;18(1):377. 8. Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, et al. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine. 2019 Jun 27;37(29):3793-3803. 9. Zou X, House BL, Zyzak MD, et al. Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum. Malaria Journal. 2013 Nov 5;12:394. 10. McCoy ME, Golden HE, Doll TA, Yang Y, Kaba SA, Zou X, et al. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. Malaria Journal. 2013 Apr 22;12:136. 11. Plassmeyer ML, Reiter K, Shimp RL Jr, Kotova S, Smith PD, Hurt DE, House B, Zou X, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. Journal of Biology Chemistry. 2009 Sep 25;284(39):26951-63. 12. Zou X, Shinde Patil VR, Dagia NM, et al. PSGL-1 derived from human neutrophils is a high-efficiency ligand for endothelium-expressed E-selectin under flow. American Journal of Physiology- Cell Physiology. 2005;289(2):C415-C424. 13. Sundd P, Zou X, Goetz DJ, Tees DF. Leukocyte adhesion in capillary-sized, P-selectin-coated micropipettes. Microcirculation. 2008;15(2):109-122.